This study of the Indian Pharmaceutical Industry (IPI) attempts to identify existing and proposed business models for the choice of strategic options for the success of the Indian pharmaceutical industry in the New Patent Regime. As part of the study, a number of company and industry reports,...

The aim of this paper is to study the labor demand in the Italian manufacturing, using firm level data on pharmaceutical industry. The Italian pharmaceutical industry is characterized by the existence of long term labor contracts, and this fact suggests to consider labor as quasi-fixed input. In...

In the present paper, it is attempted to empirically verify the impact of economic liberalization on the R&D behaviour of Indian pharmaceutical firms controlling for the effects of several firm specific characteristics including firm size. The results from the Tobit analysis for a sample of...

Innovation policy involves trading off monopoly output and pricing today in exchange for incentives for firms to develop new products. While existing research demonstrates that expected profits fuel R&D investments, little is known about the novelty of funded projects. We expand this literature...

This paper merges patent citation data with data on pharmaceutical patent expirations, generic entry, and pricing to explore the effects of observable patent characteristics on off-patent and on-patent pharmaceutical pricing. Using a sample of drug patents facing generic entry in the 1990s, I...

GLOBAL PRICE FIXING (2nd Edition) was released by Springer at the end of 2006. This note reproduces a 2002 review of the first edition of the book by Prof. Douglas Greer. It is reproduced with the permission of the publisher of the Review of Industrial Organization

We examine trends in the productivity of the pharmaceutical sector over the past three decades. Motivated by Ricardo's insight that productivity and rents are endogenous to demand when inputs are scarce, we examine the industry's aggregate R&D production function. Using exogenous demand shocks...

We draw from documented characteristics of the biopharmaceutical industry to construct a model where two firms can choose to outsource R&D to an external unit, and/or engage in internal R&D, before competing in a final market. We investigate the distribution of profits among market...